Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy

Unlike conventional antibodies, heavy chain only antibodies derived from camel contain a single variable domain (VHH) and two constant domains (CH2 and CH3). Cloned and isolated VHHs possess unique properties that enable them to excel conventional therapeutic antibodies and their smaller antigen-bin...

Full description

Bibliographic Details
Main Authors: Seyed Moein Moghimi, Fatemeh Rahbarizadeh, Davoud Ahmadvand, Ladan Parhamifar
Format: Article
Language:English
Published: Tabriz University of Medical Sciences 2013-01-01
Series:BioImpacts
Subjects:
Online Access:http://dx.doi.org/10.5681/bi.2013.009
id doaj-6a2128123cb24bdf99d1affe48a2c4fb
record_format Article
spelling doaj-6a2128123cb24bdf99d1affe48a2c4fb2020-11-24T20:41:46ZengTabriz University of Medical SciencesBioImpacts2228-56522228-56602013-01-013114Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer TherapySeyed Moein MoghimiFatemeh RahbarizadehDavoud AhmadvandLadan ParhamifarUnlike conventional antibodies, heavy chain only antibodies derived from camel contain a single variable domain (VHH) and two constant domains (CH2 and CH3). Cloned and isolated VHHs possess unique properties that enable them to excel conventional therapeutic antibodies and their smaller antigen-binding fragments in cancer targeting and therapy. VHHs express low immunogenicity, are highly robust and easy to manufacture and have the ability to recognize hidden or uncommon epitopes. We highlight the utility of VHH in design of new molecular, multifunctional particulate and immune cell-based systems for combating HER2+ breast cancer.http://dx.doi.org/10.5681/bi.2013.009Chimeric Antigen ReceptorsHeavy Chain Only AntibodiesHER2NanotechnologySingle Variable Domain
collection DOAJ
language English
format Article
sources DOAJ
author Seyed Moein Moghimi
Fatemeh Rahbarizadeh
Davoud Ahmadvand
Ladan Parhamifar
spellingShingle Seyed Moein Moghimi
Fatemeh Rahbarizadeh
Davoud Ahmadvand
Ladan Parhamifar
Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy
BioImpacts
Chimeric Antigen Receptors
Heavy Chain Only Antibodies
HER2
Nanotechnology
Single Variable Domain
author_facet Seyed Moein Moghimi
Fatemeh Rahbarizadeh
Davoud Ahmadvand
Ladan Parhamifar
author_sort Seyed Moein Moghimi
title Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy
title_short Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy
title_full Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy
title_fullStr Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy
title_full_unstemmed Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy
title_sort heavy chain only antibodies: a new paradigm in personalized her2+ breast cancer therapy
publisher Tabriz University of Medical Sciences
series BioImpacts
issn 2228-5652
2228-5660
publishDate 2013-01-01
description Unlike conventional antibodies, heavy chain only antibodies derived from camel contain a single variable domain (VHH) and two constant domains (CH2 and CH3). Cloned and isolated VHHs possess unique properties that enable them to excel conventional therapeutic antibodies and their smaller antigen-binding fragments in cancer targeting and therapy. VHHs express low immunogenicity, are highly robust and easy to manufacture and have the ability to recognize hidden or uncommon epitopes. We highlight the utility of VHH in design of new molecular, multifunctional particulate and immune cell-based systems for combating HER2+ breast cancer.
topic Chimeric Antigen Receptors
Heavy Chain Only Antibodies
HER2
Nanotechnology
Single Variable Domain
url http://dx.doi.org/10.5681/bi.2013.009
work_keys_str_mv AT seyedmoeinmoghimi heavychainonlyantibodiesanewparadigminpersonalizedher2breastcancertherapy
AT fatemehrahbarizadeh heavychainonlyantibodiesanewparadigminpersonalizedher2breastcancertherapy
AT davoudahmadvand heavychainonlyantibodiesanewparadigminpersonalizedher2breastcancertherapy
AT ladanparhamifar heavychainonlyantibodiesanewparadigminpersonalizedher2breastcancertherapy
_version_ 1716823868175286272